Motivation: Whole exome sequencing (WES) is widely adopted in clinical and research settings; however, the potential for false negatives due to incomplete breadth and depth of coverage for some exons has been reported. In some cases, targeted gene panel testing could be a reliable option to ascertain true negatives for phenotype-associated genomic variants. We developed a tool for quickly gauging whether all genes of interest are comprehensively covered by WES or whether targeted gene panel testing should instead be considered to minimize false negatives in candidate genes. Results: WEScover is a novel web application providing an interface for discovering breadth and depth of coverage across population scale WES datasets, searching either by phenotype, by targeted gene panels and by genes. Moreover, the application shows metrics from the Genome Aggregation Database to provide gene-centric view on breadth of coverage. Availability: WEScover is available at
Introduction
As the cost of whole exome sequencing (WES) drops, it is beginning to replace broad and/or targeted gene panel testing. (Stavropoulos, et al., 2016; Wang, et al., 2014) . WES for example, is superior in measurement of the ever-growing number of driver and passenger mutations in diverse genes across different cancer types as well as increasing awareness of polygenic contribution to most genetic disorders. However, WES may not capture all exons in clinically implicated genes in the human genome (Kong, et al., 2018; Meienberg, et al., 2015) . Whole genome sequencing (WGS) faces a similar challenge for some genes including highly polymorphic ones. Moreover, population scale aggregation of WES and WGS clearly shows limited breadth of coverage for some clinically implicated genes (Kong, et al., 2018; Wang, et al., 2017) . Therefore, gene panel testing, whether for a single gene or for hundreds of candidate genes, is still a clinically useful measure where false negatives due to suboptimal coverage are likely. However, it is difficult to predict whether the exons known to harbor disease-associated variants would be covered with sufficient per-site depth of coverage to reliably call variants or not. 
Implementation

Workflow
The initial query interface allows users to enter phenotype, genetic test name (retrieved from the GTR website), or official gene symbol(s) of interest. For each gene matching the query, the global mean of breadth of coverage along with its maximum and minimum values is shown as a table in an ascending order of global means (Fig. 1A) . By default, we used breadth of coverage at 20x -a threshold sufficient to achieve 99% sensitivity for detecting single nucleotide variant (Meynert, et al., 2014) . The test statistic and p-value for a one-way analysis of variance, performed to test for differences between means of populations, are also reported in this table. The button at the end of each row opens a panel with further details about the coverage of the gene. The panel first shows a table with the mean of breadth of coverage stratified by continent-level population. The second tab shows a violin plot for breadth of coverage stratified by continent-level population with the mean value from exomes in gnomAD project as a black line (Fig. 1B) . A plot for coverage at each genomic position of the selected gene, based on gnomAD coverage data, is shown next to the violin plot (Fig. 1C) A B C Fig. 1. A) The initial screen for selected genes. Clicking 'Detail' button (red highlighted box) shows window with more information for the selected transcript. B) The violin plot shows the distribution of coverage metrics from 1KGP exomes in each of 5 population. The black horizontal line denotes the global average value from gnomAD exomes. C) The coverage plot shows the transcript model and coverage metric from gnomAD exomes. The upper part of graph shows metric values at 10x (most light blue), 20x, and 30x (most dark blue).
